The PAPP-A enzyme linked immunosorbent assay (ELISA) kit provides materials for the quantitative measurement of PAPP-A in serum and other biological fluids.
| Catalog Numbers | AL-106 (RUO) Instructions for Use |
|---|---|
| Packaging | 96 well microtiter |
| Detection | HRP-based ELISA, colorimetric detection by dual wavelength absorbance at 450 nm and 630 nm as reference filter |
| Species Reactivity | Enquire about animal-specific cross-reactivity |
| Dynamic Range | 6, 18 – 3300 ng/mL |
| Limit of Detection | 1.14 ng/mL |
| Sample Size | 50 µL |
| Sample Type | Serum |
| Assay Time | 3 hours |
| Shelf Life | 24 months |
| Availability | Worldwide |
Maternal serum concentrations of pregnancy-associated plasma protein A (PAPP-A, EC 3.4.24.79, papalysin-1) are used to predict occurrence of Down syndrome. During pregnancy, PAPP-A is produced in high concentrations by the trophoblast and released into maternal circulation. In pregnancy, PAPP-A primarily circulates as 500-kDa heterotetrameric 2:2 complex with the proform of eosinophil major basic protein (proMBP), which inhibits the proteolytic activity of PAPP-A. Dimeric PAPP-A is the only active form and proteolyses IGFBP-4 and IGFBP-5. Significant amounts of active PAPP-A is reported at gestational ages between seven and thirteen weeks.
References:
1. HHS Publication, 5th ed., 2007. Biosafety in Microbiological and Biomedical Laboratories. Available http://www.cdc.gov/biosafety/publications/bmbl5/BMBL5
2. Approved Guideline – Procedures for the Handling and Processing of Blood Specimens, H18-A3. 2004. Clinical and Laboratory Standards Institute.
3. Kricka L. Interferences in immunoassays – still a threat. Clin Chem 2000; 46: 1037–1038.
PAPP-A ELISA AL-106
Espelund US, Bjerre M, Hjortebjerg R, Rasmussen TR, Lundby A, Hoeflich A, Folkersen BH, Oxvig C, Frystyk J. Insulin-Like Growth Factor Bioactivity, Stanniocalcin-2, Pregnancy-Associated Plasma Protein-A, and IGF-Binding Protein-4 in Pleural Fluid and Serum From Patients With Pulmonary Disease. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3526-3534.
All Products Cited: PAPP-A ELISA AL-106; PAPP-A2 ELISA AL-109
Hjortebjerg R, Rasmussen LM, Gude MF, Irmukhamedov A, Riber LP, Frystyk J, De Mey JGR. Local IGF Bioactivity Associates with High PAPP-A Activity in the Pericardial Cavity of Cardiovascular Disease Patients. J Clin Endocrinol Metab. 2020 Nov 1;105(11):dgaa617. doi: 10.1210/clinem/dgaa617. PMID: 32875328.
All Products Cited: IGF-I ELISA AL-121, Intact IGFBP-4 ELISA AL-126, Stanniocalcin 2 ELISA AL-143; PAPP-A ELISA AL-106
Hjortebjerg R, Thomsen KL, Agnholt J, Frystyk J. The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis. BMC Gastroenterol. 2019 Jun 3;19(1):83. doi: 10.1186/s12876-019-1000-6. PMID: 31159802; PMCID: PMC6547608.
All Products Cited: PAPP-A ELISA AL-106; Stanniocalcin 2 ELISA AL-143
Lambert-Messerlian GM, Eklund EE, Neveux LM, Palomaki GE. Measuring maternal serum screening markers for Down’s syndrome in plasma collected for cell-free DNA testing. J Med Screen. 2017 Sep;24(3):113-119.
All Products Cited: PAPP-A ELISA AL-106